ArticleAsian Pacific journal of cancer prevention : APJCP2025
Exploring The Prevalence of Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer Patients and Their Correlation with Tumor Characteristics.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis work aimed to find the incidence of TERT promoter mutations in a specific patient population and to analyze their association with various tumor characteristics.
methodsThis study, conducted from April to November 2023, involved collecting 67 formalin-fixed, paraffin-embedded (FFPE) tissue samples from patients undergoing transurethral bladder resection or radical cystectomy at the Urology Department of Almawaddah Private Hospital, Basra, Iraq. The extraction of DNA was achieved through the use of purification Promega kits. TERT gene promoter mutations, C228T AND C250T were determined by Sanger sequencing using an automated DNA sequencer, by Macrogen Corporation - Korea.
resultAmong 67 bladder cancer patients, valid pTERT molecular analysis was completed in 59 cases. Of these, 30 patients (50.85%) were found to have pTERT mutations. The most common mutation was C228T, identified in 70% (21/30) of cases, followed by C250T in 33.3% (10/30), with one patient exhibiting both mutations. No significant associations were found between TERT mutations and factors such as age, sex, or smoking status. However, these mutations were more frequently observed in low-grade tumors, occurring in 63.3% (19/30) of cases. Additionally, the prevalence of TERT mutations differed significantly between non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), with mutations detected in 60.4% (26/42) of NMIBC cases and 23.5% (4/17) of MIBC cases (p = 0.027). Although a slight difference in mutation frequency was noted between newly diagnosed and recurrent tumors, it did not reach statistical significance.
conclusionthis study demonstrates a substantial prevalence of TERT promoter mutations particularly the C228T variant in bladder cancer, which was more frequently found in NMIBC compared to MIBC. No correlations were identified between TERT mutations and demographic factors such as age, sex, or smoking history.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.